What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Gene
- Cancer
His main research concerns Immunology, Immunoglobulin E, Internal medicine, Mast cell and Systemic mastocytosis.
In most of his Immunology studies, his work intersects topics such as Molecular biology.
He has included themes like Allergen, Hypoallergenic, Recombinant DNA and Histamine in his Immunoglobulin E study.
Peter Valent interconnects Endocrinology, Surgery and Oncology in the investigation of issues within Internal medicine.
His study looks at the intersection of Mast cell and topics like Interleukin 33 with Interleukin 5.
His studies in Systemic mastocytosis integrate themes in fields like Dermatology and Urticaria pigmentosa.
His most cited work include:
- Revised International Prognostic Scoring System for Myelodysplastic Syndromes (1564 citations)
- RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia (1380 citations)
- Diagnostic criteria and classification of mastocytosis: a consensus proposal (853 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Immunology, Internal medicine, Cancer research, Systemic mastocytosis and Myeloid leukemia.
His research in Immunoglobulin E, Mast cell, Allergen, Allergy and Myeloid are components of Immunology.
Peter Valent combines subjects such as Molecular biology and Histamine with his study of Immunoglobulin E.
His studies deal with areas such as Gastroenterology, Endocrinology and Oncology as well as Internal medicine.
His work carried out in the field of Cancer research brings together such families of science as Tyrosine kinase, ABL, Leukemia and Stem cell.
Peter Valent is conducting research in Bone marrow and Disease as part of his Systemic mastocytosis study.
He most often published in these fields:
- Immunology (39.25%)
- Internal medicine (24.83%)
- Cancer research (23.72%)
What were the highlights of his more recent work (between 2016-2021)?
- Cancer research (23.72%)
- Internal medicine (24.83%)
- Systemic mastocytosis (20.82%)
In recent papers he was focusing on the following fields of study:
Peter Valent focuses on Cancer research, Internal medicine, Systemic mastocytosis, Leukemia and Myeloid leukemia.
The Cancer research study which covers Haematopoiesis that intersects with STAT5.
The Internal medicine study combines topics in areas such as Gastroenterology and Oncology.
His study looks at the relationship between Systemic mastocytosis and fields such as Tryptase, as well as how they intersect with chemical problems.
Peter Valent has researched Myeloid leukemia in several fields, including Myeloid and Tyrosine-kinase inhibitor.
His Mast cell study improves the overall literature in Immunology.
Between 2016 and 2021, his most popular works were:
- Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts (230 citations)
- BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. (118 citations)
- Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future (106 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Gene
- Cancer
His scientific interests lie mostly in Cancer research, Leukemia, Systemic mastocytosis, Immunology and Myeloid leukemia.
His Cancer research research includes elements of Cell culture, STAT5, Haematopoiesis, Stem cell and Lymphoma.
His Leukemia study combines topics in areas such as Synthetic lethality, DNA repair, Myeloid, ABL and Tyrosine-kinase inhibitor.
His Systemic mastocytosis research also covers Internal medicine, Mast cell and Disease studies.
Peter Valent combines topics linked to Angiogenesis with his work on Immunology.
Peter Valent has included themes like Tyrosine kinase, Oncology and CD38 in his Myeloid leukemia study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
